{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-007574","form_type":"8-K","ticker":"SIGY","cik":"0001642159","company_name":"Sigyn Therapeutics, Inc.","filed_at":"2026-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.727579+00:00","generated_at":"2026-05-16T01:28:08.711969+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Sigyn Therapeutics raises ~$61.5k via three convertible notes at 35% discount","bullets":["Entered three convertible note purchase agreements with Brio Capital, Osher Capital, and Lambda Venture Partners.","Total principal amount of $72,222.21 (~$61,500 net proceeds) at 8% interest per annum.","Notes convertible into common stock at a 35% discount to the lowest traded price over prior 20 trading days.","No warrants issued; issuance exempt under Section 4(a)(2) as sales to sophisticated investors.","Notes have a one-year maturity."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-007574","json":"https://secwatch.observer/filing/0001493152-26-007574.json","markdown":"https://secwatch.observer/filing/0001493152-26-007574.md","text":"https://secwatch.observer/filing/0001493152-26-007574.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642159/000149315226007574/0001493152-26-007574-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642159/000149315226007574/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:28:08.711969+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2823a345373d60760d5c434619de06648648103e","claim":"Sigyn Therapeutics, Inc. entered into Convertible Note Purchase Agreement with Osher Capital Partners, LLC valued at $22,222.22 (effective 2026-02-12).","evidence_excerpt":"On February 12, 2026, Sigyn Therapeutics, Inc. (the “Company”) entered into a one-year Convertible Note Purchase Agreement (the “Purchase Agreement”) with Osher Capital Partners, LLC, in the principal amount of $22,222.22","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642159/000149315226007574/0001493152-26-007574-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Osher Capital Partners, LLC"},{"label":"Value","value":"$22,222.22"},{"label":"Effective","value":"2026-02-12"}],"fact_type":"material_agreement"},{"claim_id":"8c6ab812e7a86a1f55580279397cf1858b486c77","claim":"Sigyn Therapeutics, Inc. entered into Convertible Note Purchase Agreement with Brio Capital Master Fund, Ltd valued at $22,222.22 (effective 2026-02-12).","evidence_excerpt":"On February 12, 2026, Sigyn Therapeutics, Inc. (the “Company”) entered into a one-year Convertible Note Purchase Agreement (the “Purchase Agreement”) with Brio Capital Master Fund, Ltd, in the principal amount of $22,222.22","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642159/000149315226007574/0001493152-26-007574-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Brio Capital Master Fund, Ltd"},{"label":"Value","value":"$22,222.22"},{"label":"Effective","value":"2026-02-12"}],"fact_type":"material_agreement"},{"claim_id":"a3a2aa68acf2db23ef9f4226e3a6f6e8ec0312c5","claim":"Sigyn Therapeutics, Inc. entered into Convertible Note Purchase Agreement with Lambda Venture Partners, LLC valued at $27,777.77 (effective 2026-02-06).","evidence_excerpt":"On February 6, 2026, Sigyn Therapeutics, Inc. (the “Company”) entered into a one-year Convertible Note Purchase Agreement (the “Purchase Agreement”) with Lambda Venture Partners, LLC, in the principal amount of $27,777.77","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642159/000149315226007574/0001493152-26-007574-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Lambda Venture Partners, LLC"},{"label":"Value","value":"$27,777.77"},{"label":"Effective","value":"2026-02-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}